Apotex Inc.
Privately held: no public share price
Assets
(5 total)
5Total Assets
5Approved
0Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | TRPV1 (transient receptor potential vanilloid 1) channelSmall molecule | Diabetic Peripheral Neuropathic Pain Diabetic Peripheral Neuropathy | |
| Approved | Voltage-gated sodium channels (Nav) on sensory nerve membranesSmall molecule | Ocular Anesthesia Ocular Surface Anesthesia | |
Modafinil(Provigil) | Approved | Sympathomimetic-like AgentSmall molecule | Narcolepsy |
| Approved | Glutathione precursor (cysteine donor)Small molecule | Toxicology / Acetaminophen Overdose Acetaminophen Overdose | |
| Approved | H. pylori eradication (PPI + amoxicillin + rifabutin)Small molecule | Helicobacter pylori Infection |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
27 October 2026PresentationCapsaicin (Qutenza)Phase III RISE results at IASP 2026: one of the primary endpoints met (average pain intensity, weeks 2-12)
20 August 2026Topline resultchloroprocaineIHEEZO contralateral-eye study vs proparacaine in intravitreal injections
US, FDA · Source ↗
Financial reports
No financial reports recorded.